These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21709191)

  • 1. Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?
    Carnevale-Schianca F; Gallo S; Rota-Scalabrini D; Sangiolo D; Fizzotti M; Caravelli D; Capaldi A; Anselmetti G; Palesandro E; D'Ambrosio L; Coha V; Obert R; Aglietta M; Grignani G
    J Clin Oncol; 2011 Aug; 29(24):e691-3. PubMed ID: 21709191
    [No Abstract]   [Full Text] [Related]  

  • 2. Bleomycin-induced pneumonitis in a young Ghanaian male with Hodgkin's Lymphoma.
    Dei-Adomakoh YA; Afriyie-Mensah JS; Gbadamosi H
    Ghana Med J; 2020 Dec; 54(4):279-283. PubMed ID: 33883778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity.
    Buchler T; Bomanji J; Lee SM
    Haematologica; 2007 Nov; 92(11):e120-1. PubMed ID: 18024389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward?
    Ravaioli A; Nicoletti S; Tamburini E; Papi M
    J Cancer Res Clin Oncol; 2009 Feb; 135(2):325-6. PubMed ID: 18825412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Arsenic treatment for leukemia: new model of human cancer target treatment].
    Zhao WW; Chen SJ
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):439-40. PubMed ID: 15854545
    [No Abstract]   [Full Text] [Related]  

  • 6. New drugs in acute myeloid leukemia.
    Grever MR
    Clin Adv Hematol Oncol; 2003 Aug; 1(8):456-9. PubMed ID: 16258431
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis.
    Yamasawa H; Sugiyama Y; Bando M; Ohno S
    Respiration; 2008; 75(3):350-4. PubMed ID: 16449804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
    Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
    Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of imatinib mesylate on bleomycin-induced pulmonary fibrosis in mice].
    Li L; Li YQ
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Apr; 19(4):229-32. PubMed ID: 17448279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate for melanoma: will a new target be revealed?
    Grossman D
    J Invest Dermatol; 2004 Dec; 123(6):xi-xiii. PubMed ID: 15610499
    [No Abstract]   [Full Text] [Related]  

  • 11. The era of personalized medicine: back to basics.
    Hutchinson L; DeVita VT
    Nat Clin Pract Oncol; 2008 Nov; 5(11):623. PubMed ID: 18957968
    [No Abstract]   [Full Text] [Related]  

  • 12. Gastrointestinal stromal tumor with metastases in an adult woman treated with imatinib mesylate: MDCT findings.
    Busalacchi PJ; de la Calle MA; Torroba A; Del Río ST
    AJR Am J Roentgenol; 2005 Mar; 184(3 Suppl):S58-61. PubMed ID: 15728023
    [No Abstract]   [Full Text] [Related]  

  • 13. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
    Abhyankar SA; Nair N
    Clin Nucl Med; 2008 Mar; 33(3):213-4. PubMed ID: 18287851
    [No Abstract]   [Full Text] [Related]  

  • 14. First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy.
    Salazar M; Barata A; André S; Venâncio J; Francisco I; Cravo M; Nobre-Leitão C
    Gut; 2006 Apr; 55(4):585-6. PubMed ID: 16531543
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified.
    Iurlo A; Fracchiolla NS; Ferla V; Cassin R; Gottardi E; Beghini A; Gianelli U; Spinelli O; Cortelezzi A
    J Clin Oncol; 2014 Apr; 32(10):e37-9. PubMed ID: 24449233
    [No Abstract]   [Full Text] [Related]  

  • 16. Current management of GISTs.
    Blanke C
    Clin Adv Hematol Oncol; 2010 May; 8(5):334. PubMed ID: 20551892
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
    Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
    J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
    [No Abstract]   [Full Text] [Related]  

  • 18. FDG positron emission tomography/computerized tomography features of bleomycin-induced pneumonitis.
    Kirsch J; Arrossi AV; Yoon JK; Wu G; Neumann DR
    J Thorac Imaging; 2006 Aug; 21(3):228-30. PubMed ID: 16915070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The giant gastrointestinal tumor of the stomach].
    Kriger AG; Kochatkov AV; Kolygin AV; Korolev SV; Konstantinova MM; Makeeva-Malinovskaia NIu
    Khirurgiia (Mosk); 2011; (2):69-72. PubMed ID: 21462593
    [No Abstract]   [Full Text] [Related]  

  • 20. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
    Yamaguchi M; Matsumoto T; Tate G; Higuchi T
    J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.